ARTICLE | Clinical News

Idera gains on psoriasis data for IMO-8400

March 28, 2014 11:58 PM UTC

Idera Pharmaceuticals Inc. (NASDAQ:IDRA) jumped on Friday after the company said IMO-8400 met the primary safety endpoint and secondary endpoint of showing clinical activity in 32 patients in a Phase II trial to treat moderate to severe plaque psoriasis. Idera gained $0.69 (18%) to $4.57 on the day. In the double-blind, placebo-controlled trial, three dose levels of once-weekly subcutaneous IMO-8400 for 12 weeks were well tolerated with no reported treatment-related discontinuations, serious adverse events or dose reductions.

IMO-8400 also met the secondary endpoint of showing clinical activity as measured by Psoriasis Area and Severity Index (PASI) responses. In patients who completed 12 weeks of treatment (n=27), IMO-8400 led to a PASI 50 response rate of 45% vs. 14% for placebo and a PASI 75 response rate of 20% vs. 0% for placebo. ...